Does the media refer more to KYMR or PVLA?

In the previous week, Kymera Therapeutics had 6 more articles in the media than Palvella Therapeutics. MarketBeat recorded 27 mentions for Kymera Therapeutics and 21 mentions for Palvella Therapeutics. Kymera Therapeutics' average media sentiment score of -0.13 beat Palvella Therapeutics' score of -0.34 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Palvella Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PCVX or PVLA more profitable?

Vaxcyte's return on equity of -37.56% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -37.56% -33.62% Palvella Therapeutics N/A -47.84% -38.33%

Does the media refer more to PCVX or PVLA?

In the previous week, Palvella Therapeutics had 2 more articles in the media than Vaxcyte. MarketBeat recorded 21 mentions for Palvella Therapeutics and 19 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.78 beat Palvella Therapeutics' score of -0.34 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is APGE or PVLA more profitable?

Apogee Therapeutics' return on equity of -32.64% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apogee Therapeutics N/A -32.64% -31.25% Palvella Therapeutics N/A -47.84% -38.33%

Does the media refer more to APGE or PVLA?

In the previous week, Palvella Therapeutics had 11 more articles in the media than Apogee Therapeutics. MarketBeat recorded 21 mentions for Palvella Therapeutics and 10 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.83 beat Palvella Therapeutics' score of -0.34 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMVT or PVLA more profitable?

Palvella Therapeutics' return on equity of -47.84% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -68.46% -62.28% Palvella Therapeutics N/A -47.84% -38.33%

Does the media prefer IMVT or PVLA?

In the previous week, Palvella Therapeutics had 12 more articles in the media than Immunovant. MarketBeat recorded 21 mentions for Palvella Therapeutics and 9 mentions for Immunovant. Immunovant's average media sentiment score of 0.39 beat Palvella Therapeutics' score of -0.34 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palvella Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RYTM or PVLA?

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Palvella Therapeutics. MarketBeat recorded 24 mentions for Rhythm Pharmaceuticals and 21 mentions for Palvella Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 0.53 beat Palvella Therapeutics' score of -0.34 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Palvella Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Palvella Therapeutics (PVLA) Competitors

$157.77 +2.84 (+1.83%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$157.78 +0.01 (+0.01%)

As of 08/7/2026 07:34 PM Eastern

Compare

PVLA vs. KYMR, PCVX, APGE, IMVT, and RYTM

Should you buy Palvella Therapeutics stock or one of its competitors? MarketBeat compares Palvella Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Palvella Therapeutics include Kymera Therapeutics (KYMR), Vaxcyte (PCVX), Apogee Therapeutics (APGE), Immunovant (IMVT), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "biotechnology" industry.

How does Palvella Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Palvella Therapeutics (NASDAQ:PVLA) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Kymera Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market.

Palvella Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.82% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.82%	-19.66%
Palvella Therapeutics	N/A	-47.84%	-38.33%

In the previous week, Kymera Therapeutics had 6 more articles in the media than Palvella Therapeutics. MarketBeat recorded 27 mentions for Kymera Therapeutics and 21 mentions for Palvella Therapeutics. Kymera Therapeutics' average media sentiment score of -0.13 beat Palvella Therapeutics' score of -0.34 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palvella Therapeutics	3 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palvella Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$105M	85.15	-$311.35M	-$3.24	N/A
Palvella Therapeutics	$42.81M	53.11	-$41.72M	-$4.83	N/A

40.1% of Palvella Therapeutics shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Kymera Therapeutics currently has a consensus price target of $125.65, suggesting a potential upside of 16.86%. Palvella Therapeutics has a consensus price target of $209.14, suggesting a potential upside of 32.56%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Palvella Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Kymera Therapeutics beats Palvella Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Palvella Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Palvella Therapeutics (NASDAQ:PVLA) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Vaxcyte has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 3.3% of Vaxcyte shares are held by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Palvella Therapeutics has higher revenue and earnings than Vaxcyte. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Palvella Therapeutics	$42.81M	53.11	-$41.72M	-$4.83	N/A

Vaxcyte presently has a consensus target price of $86.00, suggesting a potential upside of 48.10%. Palvella Therapeutics has a consensus target price of $209.14, suggesting a potential upside of 32.56%. Given Vaxcyte's higher probable upside, equities research analysts clearly believe Vaxcyte is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Vaxcyte's return on equity of -37.56% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Palvella Therapeutics	N/A	-47.84%	-38.33%

In the previous week, Palvella Therapeutics had 2 more articles in the media than Vaxcyte. MarketBeat recorded 21 mentions for Palvella Therapeutics and 19 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.78 beat Palvella Therapeutics' score of -0.34 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	3 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Palvella Therapeutics beats Vaxcyte on 8 of the 15 factors compared between the two stocks.

How does Palvella Therapeutics compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Palvella Therapeutics (NASDAQ:PVLA) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Apogee Therapeutics' return on equity of -32.64% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Palvella Therapeutics	N/A	-47.84%	-38.33%

In the previous week, Palvella Therapeutics had 11 more articles in the media than Apogee Therapeutics. MarketBeat recorded 21 mentions for Palvella Therapeutics and 10 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.83 beat Palvella Therapeutics' score of -0.34 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	3 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apogee Therapeutics has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market.

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Palvella Therapeutics has higher revenue and earnings than Apogee Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Palvella Therapeutics	$42.81M	53.11	-$41.72M	-$4.83	N/A

Apogee Therapeutics currently has a consensus target price of $121.25, suggesting a potential downside of 10.08%. Palvella Therapeutics has a consensus target price of $209.14, suggesting a potential upside of 32.56%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Palvella Therapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Apogee Therapeutics beats Palvella Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Palvella Therapeutics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Palvella Therapeutics (NASDAQ:PVLA) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Immunovant has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market.

In the previous week, Palvella Therapeutics had 12 more articles in the media than Immunovant. MarketBeat recorded 21 mentions for Palvella Therapeutics and 9 mentions for Immunovant. Immunovant's average media sentiment score of 0.39 beat Palvella Therapeutics' score of -0.34 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palvella Therapeutics	3 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palvella Therapeutics' return on equity of -47.84% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-68.46%	-62.28%
Palvella Therapeutics	N/A	-47.84%	-38.33%

Immunovant currently has a consensus target price of $44.00, suggesting a potential upside of 10.14%. Palvella Therapeutics has a consensus target price of $209.14, suggesting a potential upside of 32.56%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Palvella Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

47.1% of Immunovant shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 1.9% of Immunovant shares are held by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Palvella Therapeutics has higher revenue and earnings than Immunovant. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Palvella Therapeutics	$42.81M	53.11	-$41.72M	-$4.83	N/A

Summary

Palvella Therapeutics beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does Palvella Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Palvella Therapeutics (NASDAQ:PVLA) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Rhythm Pharmaceuticals presently has a consensus price target of $142.44, indicating a potential upside of 23.18%. Palvella Therapeutics has a consensus price target of $209.14, indicating a potential upside of 32.56%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Palvella Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Rhythm Pharmaceuticals has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Palvella Therapeutics. MarketBeat recorded 24 mentions for Rhythm Pharmaceuticals and 21 mentions for Palvella Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 0.53 beat Palvella Therapeutics' score of -0.34 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Palvella Therapeutics	3 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palvella Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Palvella Therapeutics' return on equity of -47.84% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Palvella Therapeutics	N/A	-47.84%	-38.33%

Palvella Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$239.92M	33.03	-$196.54M	-$3.11	N/A
Palvella Therapeutics	$42.81M	53.11	-$41.72M	-$4.83	N/A

40.1% of Palvella Therapeutics shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Palvella Therapeutics beats Rhythm Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Palvella Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PVLA vs. The Competition

Export

Metric	Palvella Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.27B	$3.69B	$7.02B	$13.01B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-32.66	9.02	271.11	25.19
Price / Sales	53.11	1,255.27	581.13	76.02
Price / Cash	N/A	102.35	71.81	50.72
Price / Book	10.48	18.10	13.25	6.22
Net Income	-$41.72M	-$13.25M	$3.45B	$342.66M
7 Day Performance	13.47%	6.24%	4.67%	4.41%
1 Month Performance	4.46%	-3.50%	-1.28%	-1.10%
1 Year Performance	285.75%	61.28%	77.33%	23.99%

Palvella Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PVLA Palvella Therapeutics	2.9938 of 5 stars	$157.77 +1.8%	$209.14 +32.6%	+285.7%	$2.27B	$42.81M	N/A	N/A	News Coverage Earnings Report Analyst Forecast Analyst Revision Gap Up
KYMR Kymera Therapeutics	1.6934 of 5 stars	$106.41 +0.9%	$125.65 +18.1%	+164.7%	$8.75B	$51.48M	N/A	170	Earnings Report Analyst Forecast Analyst Revision
PCVX Vaxcyte	2.7413 of 5 stars	$58.89 +5.3%	$86.00 +46.0%	+94.2%	$8.50B	N/A	N/A	160	News Coverage Earnings Report Analyst Upgrade Insider Trade
APGE Apogee Therapeutics	1.87 of 5 stars	$134.49 +0.2%	$121.25 -9.8%	+281.0%	$8.32B	N/A	N/A	91	News Coverage Upcoming Earnings Insider Trade
IMVT Immunovant	1.7246 of 5 stars	$39.74 +1.2%	$44.00 +10.7%	+158.4%	$8.20B	N/A	N/A	120	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PVLA) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palvella Therapeutics (PVLA) Competitors

PVLA vs. KYMR, PCVX, APGE, IMVT, and RYTM

How does Palvella Therapeutics compare to Kymera Therapeutics?

Summary

How does Palvella Therapeutics compare to Vaxcyte?

Summary

How does Palvella Therapeutics compare to Apogee Therapeutics?

Summary

How does Palvella Therapeutics compare to Immunovant?

Summary

How does Palvella Therapeutics compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA vs. The Competition

Palvella Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palvella Therapeutics (PVLA) Competitors

PVLA vs. KYMR, PCVX, APGE, IMVT, and RYTM

How does Palvella Therapeutics compare to Kymera Therapeutics?

Which has more volatility and risk, KYMR or PVLA?

Is KYMR or PVLA more profitable?

Does the media refer more to KYMR or PVLA?

Which has higher valuation and earnings, KYMR or PVLA?

Do insiders & institutionals hold more shares of KYMR or PVLA?

Do analysts recommend KYMR or PVLA?

Summary

How does Palvella Therapeutics compare to Vaxcyte?

Which has more risk & volatility, PCVX or PVLA?

Do institutionals and insiders hold more shares of PCVX or PVLA?

Which has preferable earnings & valuation, PCVX or PVLA?

Do analysts recommend PCVX or PVLA?

Is PCVX or PVLA more profitable?

Does the media refer more to PCVX or PVLA?

Summary

How does Palvella Therapeutics compare to Apogee Therapeutics?

Is APGE or PVLA more profitable?

Does the media refer more to APGE or PVLA?

Which has more risk & volatility, APGE or PVLA?

Do institutionals & insiders hold more shares of APGE or PVLA?

Which has preferable valuation and earnings, APGE or PVLA?

Do analysts prefer APGE or PVLA?

Summary

How does Palvella Therapeutics compare to Immunovant?

Which has more volatility and risk, IMVT or PVLA?

Does the media prefer IMVT or PVLA?

Is IMVT or PVLA more profitable?

Do analysts recommend IMVT or PVLA?

Do insiders & institutionals hold more shares of IMVT or PVLA?

Which has better earnings and valuation, IMVT or PVLA?

Summary

How does Palvella Therapeutics compare to Rhythm Pharmaceuticals?

Do analysts rate RYTM or PVLA?

Which has more risk and volatility, RYTM or PVLA?

Does the media refer more to RYTM or PVLA?

Is RYTM or PVLA more profitable?

Which has better valuation and earnings, RYTM or PVLA?

Do institutionals and insiders have more ownership in RYTM or PVLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA vs. The Competition

Palvella Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools